DD242229A5 - Verfahren zur herstellung von neuen derivaten der alpha-/oxo-2-hexahydro-2,4,5,6,7a thieno (3,2-c) pyridyl-5) phenyl-essig-saurer saeure - Google Patents

Verfahren zur herstellung von neuen derivaten der alpha-/oxo-2-hexahydro-2,4,5,6,7a thieno (3,2-c) pyridyl-5) phenyl-essig-saurer saeure Download PDF

Info

Publication number: DD242229A5
Authority: DD; German Democratic Republic
Prior art keywords: formula; radical; thieno; acid; carbon atoms
Prior art date: 1985-01-31

Application number

DD85285569A

Other languages

German (de)

English (en)

Inventor

Alain Badorc

Daniel Frehel

Jean-Pierre Maffrand

Eric Vallee

Original Assignee

K

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-01-31

Filing date

1985-12-27

Publication date

1987-01-21

1985-12-27 Application filed by K filed Critical K

1987-01-21 Publication of DD242229A5 publication Critical patent/DD242229A5/de

Links

239000002253 acid Substances 0.000 title claims abstract description 19
238000004519 manufacturing process Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 31
208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 12
239000003814 drug Substances 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 7
150000007513 acids Chemical class 0.000 claims abstract description 4
229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
239000011707 mineral Substances 0.000 claims abstract description 4
150000007524 organic acids Chemical class 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims abstract description 4
235000005985 organic acids Nutrition 0.000 claims abstract description 3
239000003146 anticoagulant agent Substances 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 29
-1 alkyl radical Chemical class 0.000 claims description 23
150000002148 esters Chemical class 0.000 claims description 23
239000000460 chlorine Substances 0.000 claims description 14
150000001408 amides Chemical class 0.000 claims description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 11
230000002785 anti-thrombosis Effects 0.000 claims description 10
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
239000012429 reaction media Substances 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 8
229960005001 ticlopidine Drugs 0.000 claims description 8
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 8
230000004913 activation Effects 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
150000001638 boron Chemical class 0.000 claims description 7
239000012442 inert solvent Substances 0.000 claims description 7
229940125670 thienopyridine Drugs 0.000 claims description 7
239000002175 thienopyridine Substances 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 6
230000007062 hydrolysis Effects 0.000 claims description 6
238000006460 hydrolysis reaction Methods 0.000 claims description 6
230000000144 pharmacologic effect Effects 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
238000009835 boiling Methods 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
238000005903 acid hydrolysis reaction Methods 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims description 3
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
208000001435 Thromboembolism Diseases 0.000 claims description 2
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims description 2
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
150000007530 organic bases Chemical class 0.000 claims description 2
231100000915 pathological change Toxicity 0.000 claims description 2
230000036285 pathological change Effects 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical compound [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 claims 1
WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims 1
230000000702 anti-platelet effect Effects 0.000 claims 1
238000006482 condensation reaction Methods 0.000 claims 1
JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims 1
230000023597 hemostasis Effects 0.000 claims 1
125000004475 heteroaralkyl group Chemical group 0.000 claims 1
230000003301 hydrolyzing effect Effects 0.000 claims 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 claims 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
150000003254 radicals Chemical class 0.000 claims 1
238000009833 condensation Methods 0.000 abstract description 6
230000005494 condensation Effects 0.000 abstract description 6
230000002401 inhibitory effect Effects 0.000 abstract description 6
229960004676 antithrombotic agent Drugs 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000013078 crystal Substances 0.000 description 24
238000012360 testing method Methods 0.000 description 19
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
239000000243 solution Substances 0.000 description 17
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
230000029936 alkylation Effects 0.000 description 8
238000005804 alkylation reaction Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
230000002152 alkylating effect Effects 0.000 description 6
238000010171 animal model Methods 0.000 description 6
239000002585 base Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
125000001309 chloro group Chemical group Cl* 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
230000002776 aggregation Effects 0.000 description 5
238000004220 aggregation Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
238000001816 cooling Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
229960004279 formaldehyde Drugs 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
150000002641 lithium Chemical class 0.000 description 3
238000005259 measurement Methods 0.000 description 3
235000015497 potassium bicarbonate Nutrition 0.000 description 3
229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
239000011736 potassium bicarbonate Substances 0.000 description 3
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
235000009518 sodium iodide Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 3
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002744 anti-aggregatory effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
235000011837 pasties Nutrition 0.000 description 2
229960003424 phenylacetic acid Drugs 0.000 description 2
239000003279 phenylacetic acid Substances 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical class C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
NRGKFNDKBDBBGY-UHFFFAOYSA-N 1h-pyridin-2-one;hydrochloride Chemical compound Cl.O=C1C=CC=CN1 NRGKFNDKBDBBGY-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
235000021552 granulated sugar Nutrition 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000006263 metalation reaction Methods 0.000 description 1
XOIOYHPJZJLTGK-UHFFFAOYSA-N methyl 2-chloro-2-phenylacetate Chemical compound COC(=O)C(Cl)C1=CC=CC=C1 XOIOYHPJZJLTGK-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
LWRYDHOHXNQTSK-UHFFFAOYSA-N thiophene oxide Chemical group O=S1C=CC=C1 LWRYDHOHXNQTSK-UHFFFAOYSA-N 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

DD85285569A 1985-01-31 1985-12-27 Verfahren zur herstellung von neuen derivaten der alpha-/oxo-2-hexahydro-2,4,5,6,7a thieno (3,2-c) pyridyl-5) phenyl-essig-saurer saeure DD242229A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8501908A FR2576901B1 (fr)	1985-01-31	1985-01-31	Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique

Publications (1)

Publication Number	Publication Date
DD242229A5 true DD242229A5 (de)	1987-01-21

Family

ID=9316132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD85285569A DD242229A5 (de)	1985-01-31	1985-12-27	Verfahren zur herstellung von neuen derivaten der alpha-/oxo-2-hexahydro-2,4,5,6,7a thieno (3,2-c) pyridyl-5) phenyl-essig-saurer saeure

Country Status (24)

Country	Link
US (1)	US4740510A (cs)
EP (1)	EP0192535A1 (cs)
JP (1)	JPS61246186A (cs)
AU (1)	AU581487B2 (cs)
CA (1)	CA1265517A (cs)
CS (1)	CS253741B2 (cs)
DD (1)	DD242229A5 (cs)
DK (1)	DK157553C (cs)
ES (1)	ES8703881A1 (cs)
FI (1)	FI860473L (cs)
FR (1)	FR2576901B1 (cs)
GR (1)	GR860287B (cs)
HU (1)	HU193625B (cs)
IL (1)	IL77598A (cs)
MA (1)	MA20619A1 (cs)
NO (1)	NO162965C (cs)
NZ (1)	NZ214982A (cs)
OA (1)	OA08196A (cs)
PL (1)	PL145159B1 (cs)
PT (1)	PT81946B (cs)
SU (1)	SU1389679A3 (cs)
TN (1)	TNSN86012A1 (cs)
YU (1)	YU11986A (cs)
ZA (1)	ZA86407B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2652579B1 (fr) *	1989-10-02	1992-01-24	Sanofi Sa	Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
FI101150B (fi) *	1991-09-09	1998-04-30	Sankyo Co	Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
DE69526443T2 (de) *	1994-10-07	2002-12-12	Ube Industries, Ltd.	2-silyloxy-tetrahydrothienopyridin, sein salz und verfahren zu seiner herstellung
NZ334389A (en) *	1996-08-28	2001-05-25	Ube Industries	Cyclic amine derivatives
AU737303B2 (en) *	1998-02-27	2001-08-16	Sankyo Company Limited	Cyclic amino compounds
DK1298132T3 (da)	2000-07-06	2007-03-12	Sankyo Co	Hydropyridinderivatsyreadditionssalte
CZ297570B6 (cs) *	2000-12-25	2007-02-07	Sankyo Company, Limited	Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití
GB0125708D0 (en) *	2001-10-26	2001-12-19	Generics Uk Ltd	Novel compounds and processes
CZ302135B6 (cs) *	2007-07-09	2010-11-10	Zentiva, A. S.	Zpusob výroby 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4, 5, 6, 7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu)
EP2205611A4 (en) *	2007-11-09	2012-02-22	Reddys Lab Ltd Dr	PROCESS FOR THE PRODUCTION OF PRASUGREL AND SALTS AND POLYMERS THEREOF
WO2009066326A2 (en) *	2007-11-19	2009-05-28	Msn Laboratories Limited	Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
CN101289454B (zh) *	2008-06-10	2011-02-16	上海医药工业研究院	2-氧-2,4,5,6,7,7α-六氢噻吩并[3,2-c]吡啶的制备方法
DE102008046630A1 (de) *	2008-09-10	2010-03-11	Emitec Gesellschaft Für Emissionstechnologie Mbh	Modulares Tanksystem für ein flüssiges Reduktionsmittel mit einem Sumpfelement
CN101402643B (zh) *	2008-11-11	2012-11-28	上海现代制药股份有限公司	一种适于工业生产的普拉格雷的制备方法
CN101402593A (zh) *	2008-11-11	2009-04-08	上海现代制药股份有限公司	用于制备普拉格雷的中间体及其制备方法
CZ2008748A3 (cs)	2008-11-26	2010-06-02	Zentiva, A. S	Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c] pyridin-2-yl acetátu, prasugrelu
US20120202066A1 (en) *	2009-10-07	2012-08-09	Manne Satyanarayana Reddy	Processes For Preparing Prasugrel And Pharmaceutically Acceptable Salts Thereof
HU229035B1 (en)	2009-12-21	2013-07-29	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Process for producing prasurgel
HU229031B1 (en)	2009-12-21	2013-07-29	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Process for producing prasurgel and its intermediate
CN102863457B (zh) *	2010-02-02	2013-10-09	江苏威凯尔医药科技有限公司	光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102869668A (zh)	2010-03-09	2013-01-09	斯索恩有限公司	制备普拉格雷的方法
CN102212069A (zh) *	2010-04-06	2011-10-12	刘桂坤	环烷衍生物及其制备方法和在心脑血管病药物上的应用
CN101845052B (zh) *	2010-06-11	2012-01-11	天津药物研究院	一类含氮杂环的噻吩并吡啶酮衍生物、其制备方法和用途
KR20130101517A (ko)	2010-08-26	2013-09-13	아이피시에이 래버러토리즈 리미티드	혈전증 또는 색전증의 치료 또는 예방 방법
CN101948479B (zh) *	2010-09-29	2013-01-30	横店集团家园化工有限公司	普拉格雷中间体及其制备方法
CN102002056B (zh) *	2010-11-02	2012-04-25	北京赛科药业有限责任公司	一种普拉格雷中间体的制备方法
CN101985451B (zh) *	2010-11-02	2012-04-25	北京赛科药业有限责任公司	普拉格雷中间体的制备方法
CN102276623A (zh) *	2011-06-13	2011-12-14	安徽省虹升生物科技有限公司	一种利用有机硅保护剂进行制备普拉格雷的新方法
WO2013001544A1 (en) *	2011-06-27	2013-01-03	Ipca Laboratories Limited	Anti-thrombotic compounds
CN104341433B (zh) *	2013-08-02	2017-12-15	鲁南制药集团股份有限公司	一种普拉格雷中间体的制备方法
CN104447867B (zh) *	2013-09-17	2017-12-26	江苏天士力帝益药业有限公司	一种噻吩并哌啶衍生物、制备方法及其应用
CN107698620A (zh)	2015-06-23	2018-02-16	江苏天士力帝益药业有限公司	一种氘代噻吩并哌啶衍生物、制备方法及其应用
CN108570060A (zh) *	2018-05-13	2018-09-25	日照市普达医药科技有限公司	一种4,5,6,7-四氢噻吩并[3,2-c]吡啶类衍生物对血栓的治疗作用
CA3119835A1 (en)	2018-11-13	2020-05-22	Rubicon Oilfield International, Inc.	Three axis vibrating device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2495157A1 (fr) *	1980-11-28	1982-06-04	Sanofi Sa	Procede nouveau de preparation des tetrahydro-5, 6, 7, 7a 4h-thieno (3, 2-c) pyridinones-2
FR2495156A1 (fr) *	1980-11-28	1982-06-04	Sanofi Sa	Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2528848A1 (fr) *	1982-06-16	1983-12-23	Sanofi Sa	Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
FR2530247B1 (fr) *	1982-07-13	1986-05-16	Sanofi Sa	Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
DE3302125A1 (de) *	1983-01-22	1984-07-26	Boehringer Ingelheim KG, 6507 Ingelheim	Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung

1985
- 1985-01-31 FR FR8501908A patent/FR2576901B1/fr not_active Expired
- 1985-12-27 DD DD85285569A patent/DD242229A5/de unknown
- 1985-12-27 ES ES550448A patent/ES8703881A1/es not_active Expired
1986
- 1986-01-14 IL IL77598A patent/IL77598A/xx unknown
- 1986-01-16 AU AU52424/86A patent/AU581487B2/en not_active Ceased
- 1986-01-20 ZA ZA86407A patent/ZA86407B/xx unknown
- 1986-01-22 SU SU864010535A patent/SU1389679A3/ru active
- 1986-01-27 MA MA20844A patent/MA20619A1/fr unknown
- 1986-01-27 CA CA000500411A patent/CA1265517A/fr not_active Expired - Fee Related
- 1986-01-29 YU YU00119/86A patent/YU11986A/xx unknown
- 1986-01-29 PL PL1986257691A patent/PL145159B1/pl unknown
- 1986-01-30 PT PT81946A patent/PT81946B/pt not_active IP Right Cessation
- 1986-01-30 CS CS86675A patent/CS253741B2/cs unknown
- 1986-01-30 DK DK047186A patent/DK157553C/da not_active IP Right Cessation
- 1986-01-30 NZ NZ214982A patent/NZ214982A/xx unknown
- 1986-01-30 GR GR860287A patent/GR860287B/el unknown
- 1986-01-30 NO NO860332A patent/NO162965C/no unknown
- 1986-01-30 OA OA58777A patent/OA08196A/xx unknown
- 1986-01-31 FI FI860473A patent/FI860473L/fi not_active Application Discontinuation
- 1986-01-31 JP JP61020006A patent/JPS61246186A/ja active Pending
- 1986-01-31 EP EP86400215A patent/EP0192535A1/fr not_active Withdrawn
- 1986-01-31 TN TNTNSN86012A patent/TNSN86012A1/fr unknown
- 1986-01-31 US US06/825,068 patent/US4740510A/en not_active Expired - Fee Related
- 1986-01-31 HU HU86456A patent/HU193625B/hu not_active IP Right Cessation

Also Published As

Publication number	Publication date
OA08196A (fr)	1987-10-30
NO860332L (no)	1986-08-01
IL77598A (en)	1988-12-30
PT81946B (pt)	1987-12-30
DK157553B (da)	1990-01-22
PL145159B1 (en)	1988-08-31
PT81946A (fr)	1986-02-01
EP0192535A1 (fr)	1986-08-27
AU5242486A (en)	1986-08-07
AU581487B2 (en)	1989-02-23
ES8703881A1 (es)	1987-03-01
NZ214982A (en)	1988-04-29
CS253741B2 (en)	1987-12-17
FR2576901B1 (fr)	1987-03-20
TNSN86012A1 (fr)	1990-01-01
ES550448A0 (es)	1987-03-01
FI860473A7 (fi)	1986-08-01
FI860473L (fi)	1986-08-01
HU193625B (en)	1987-11-30
NO162965C (no)	1990-03-14
SU1389679A3 (ru)	1988-04-15
GR860287B (en)	1986-06-02
CA1265517A (fr)	1990-02-06
HUT40440A (en)	1986-12-28
MA20619A1 (fr)	1986-10-01
NO162965B (no)	1989-12-04
US4740510A (en)	1988-04-26
YU11986A (en)	1987-08-31
PL257691A1 (en)	1986-11-04
FI860473A0 (fi)	1986-01-31
DK47186A (da)	1986-08-01
ZA86407B (en)	1986-09-24
JPS61246186A (ja)	1986-11-01
FR2576901A1 (fr)	1986-08-08
DK47186D0 (da)	1986-01-30
DK157553C (da)	1990-06-11

Publication	Publication Date	Title
DD242229A5 (de)	1987-01-21	Verfahren zur herstellung von neuen derivaten der alpha-/oxo-2-hexahydro-2,4,5,6,7a thieno (3,2-c) pyridyl-5) phenyl-essig-saurer saeure
DD211351A5 (de)	1984-07-11	Verfahren zur herstellung von neuen thieno-(3,2-c)pyridin-derivaten
DE2149249B2 (de)	1974-11-07	4-Amino-6-arylpyrimidine
DE69023980T2 (de)	1996-08-01	2-(RS)-substituierte-2,3-dihydro-5-oxy-4,6,7-trimethyl-benzofurane, verwendbar als antioxydante Arzneimittel mit mukoregulierender und anti-ischemischer Wirkung.
DE2537070C2 (cs)	1987-06-25
DE2846931C2 (cs)	1988-12-01
DD201903A5 (de)	1983-08-17	Verfahren zur herstellung von derivaten des thienopyridonons
DE2634903A1 (de)	1977-02-17	Neue thienopyridinderivate und sie enthaltende arzneimittel
DD297822A5 (de)	1992-01-23	Neue 1h, 3h-pyrrol(1,2-c)thiazolcarboxamid-7-derivate, ihre herstellung und sie enthaltende pharmazeutische verbindungen
EP0133530A2 (de)	1985-02-27	1,6-Naphthyridinon-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DD233847A5 (de)	1986-03-12	Verfahren zur herstellung von methylendiphosphon-derivaten mit antireuhmatischen eigenschaften
DE2730832A1 (de)	1978-01-19	Thieno-(2,3-c)- und -(3,2-c)pyridine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2831761C2 (de)	1984-12-13	2,3- und 2,3,6-substituierte-4-Pyrone und deren Verwendung
DE2602643A1 (de)	1977-07-28	1,2-benzisothiazolinone-3, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DD210051A5 (de)	1984-05-30	Verfahren zur darstellung eines neuen thienopyridinon-derivats
CH621780A5 (cs)	1981-02-27
DE1816993A1 (de)	1969-10-16	Verfahren zur Herstellung von 1-Aoyl- oder 1-Heteroaroyl- oder 1-Benzheteroaroyl-2-methyl-5-alkoxy-(oder 5-aralkoxy)-indolyl-3-essigsaeuren
DD151448A5 (de)	1981-10-21	Verfahren zur herstellung von benzothiazolderivaten
DE2618936C3 (de)	1979-05-03	N-Acyl-glutamine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
CH644596A5 (de)	1984-08-15	2,6-dimethyl-1,4-dihydropyridin-3,5-dikarbonsaeureester und verfahren zu ihrer herstellung.
DE2907379A1 (de)	1979-09-06	Benzylidenderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DD213216A5 (de)	1984-09-05	Verfahren zur herstellung eines neuen pynolidin-derivates
DE69520876T2 (de)	2002-02-21	Gamma-diketonverbindung mit thrombozytenaggregationshemmender wirkung
DE2530515C2 (de)	1983-12-01	4- bzw. 7-Hydroxy-4,5,6,7-tetrahydrothieno-[3,2-c] bzw.[2,3-c] pyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittelzubereitungen
DE3104883C2 (de)	1984-11-15	Benzylidenderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel